2.08
-0.115(-5.25%)
Currency In USD
| Previous Close | 2.19 |
| Open | 2.21 |
| Day High | 2.22 |
| Day Low | 2.05 |
| 52-Week High | 11.57 |
| 52-Week Low | 0.61 |
| Volume | 700,420 |
| Average Volume | 1.6M |
| Market Cap | 346.56M |
| PE | -1.41 |
| EPS | -1.47 |
| Moving Average 50 Days | 2.28 |
| Moving Average 200 Days | 1.48 |
| Change | -0.12 |
If you invested $1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth $127.69 as of December 09, 2025 at a share price of $2.075. Whereas If you bought $1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 1 year ago, it would be worth $200.1 as of December 09, 2025 at a share price of $2.075.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbi
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
GlobeNewswire Inc.
Oct 27, 2025 10:30 AM GMT
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven by best-in-c
Neumora Therapeutics to Host Virtual R&D Day on October 27
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad r